Treatment of epilepsy often requires a multilevel approach that includes:
Epilepsy is the most well-known neurologic disorder in which CBD has shown promise.1 Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are severe epilepsy disorders, which most often begin in early childhood. Tuberous sclerosis complex (TSC) is a genetic disease that commonly manifests as focal seizures. Patients with DS, LGS, and TSC have seizures resistant to common antiepileptic medications and mutations in endocannabinoid and other receptors regulating brain hyperexcitability, which make these diseases difficult to treat with most targeted therapies.2-4
Clinical trials have demonstrated that CBD treatment, as an add-on therapy to antiseizure medications, reduces seizures in patients with DS, LGS, TSC, or other forms of drug-resistant epilepsy with a tolerable toxicity profile.2,5
Epilepsy continues to be the most common therapeutic area for ongoing CBD clinical trials. Other areas of study for CBD include Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, neuropathic pain, anxiety, depression, schizophrenia, and psychosis.
